Skip to main content

Table 6 Association of both or either COL11A1 A and E variants with clinicopathological characteristics in breast cancer tissues

From: Development of novel real-time PCR methodology for quantification of COL11A1 mRNA variants and evaluation in breast cancer tissue specimens

Clinical features

Ν (%)

Both Variant A & E

Rest

Pearson χ 2 or Fisher’s exact

N (%)

Either Variant A OR E

No variant

Pearson χ 2 or Fisher’s exact

n (%)

n (%)

p-value

n (%)

n (%)

p-value

Age Group

   

0.036

   

0.535

  < =50 years

26 (35.6)

3 (15.8)

23 (42.6)

 

26 (35.6)

17 (33.3)

9 (40.9)

 

  > 50 years

47 (64.4)

16 (84.2)

31 (57.4)

 

47 (64.4)

34 (66.7)

13 (59.1)

 

Tumor Size

   

0.778

   

0.778

  ≤ 2.0 cm

59 (67.0)

18 (69.2)

41 (66.1)

 

59 (67.0)

41 (66.1)

18 (69.2)

 

  > 2.0 cm

29 (33.0)

8 (30.8)

21 (33.9)

 

29 (33.0)

21 (33.9)

8 (30.8)

 

Histopathological Type

   

0.733

   

0.642

 Lobular & rest

18 (20.0)

5 (17.9)

13 (21.0)

 

18 (20.0)

12 (18.8)

6 (23.1)

 

 Intraductal infiltrating

72 (80.0)

23 (82.1)

49 (79.0)

 

72 (80.0)

52 (81.3)

20 (76.9)

 

Lymph-node Involvement

   

0.571

   

0.072

 Negative (Ν0)

55 (67.1)

15 (62.5)

40 (69.0)

 

55 (67.1)

34 (60.7)

21 (80.8)

 

 Positive (Ν+)

27 (32.9)

9 (37.5)

18 (31.0)

 

27 (32.9)

22 (39.3)

5 (19.2)

 

Metastasis

   

0.098

   

0.043

 Negative M0

47 (85.5)

13 (72.2)

34 (91.9)

 

47 (85.5)

29 (78.4)

18 (100.0)

 

 Positive M1

8 (14.5)

5 (27.8)

3 (8.1)

 

8 (14.5)

8 (21.6)

0 (0.0)

 

Grade

   

0.215

   

0.810

 Low (1–2)

60 (73.2)

16 (64.0)

44 (77.2)

 

60 (73.2)

42 (72.4)

18 (75.0)

 

 High (3)

22 (26.8)

9 (36.0)

13 (22.8)

 

22 (26.8)

16 (27.6)

6 (25.0)

 

Estrogen-receptor Status

   

0.166

   

0.509

 Negative

21 (23.9)

9 (33.3)

12 (19.7)

 

21 (23.9)

16 (25.8)

5 (19.2)

 

 Positive

67 (76.1)

18 (66.7)

49 (80.3)

 

67 (76.1)

46 (74.2)

21 (80.8)

 

Progesterone-receptor Status

   

0.383

   

0.457

 Negative

46 (52.3)

16 (59.3)

30 (49.2)

 

46 (52.3)

34 (54.8)

12 (46.2)

 

 Positive

42 (47.7)

11 (40.7)

31 (50.8)

 

42 (47.7)

28 (45.2)

14 (53.8)

 

HER2 Overexpression Status

   

0.546

   

0.375

 Negative

72 (81.8)

20 (76.9)

52 (83.9)

 

72 (81.8)

49 (79.0)

23 (88.5)

 

 Positive

16 (18.2)

6 (23.1)

10 (16.1)

 

16 (18.2)

13 (21.0)

3 (11.5)

 

TNBC, n (%)

   

0.646

   

0.563

 Yes

17 (19.3)

6 (22.2)

11 (18.0)

 

17 (19.3)

11 (17.7)

6 (23.1)

 

 No

71 (80.7)

21 (77.8)

50 (82.0)

 

71 (80.7)

51 (82.3)

20 (76.9)